LT3222617T - Psma nukreipti junginiai ir jų naudojimas - Google Patents

Psma nukreipti junginiai ir jų naudojimas

Info

Publication number
LT3222617T
LT3222617T LTEP17169052.2T LT17169052T LT3222617T LT 3222617 T LT3222617 T LT 3222617T LT 17169052 T LT17169052 T LT 17169052T LT 3222617 T LT3222617 T LT 3222617T
Authority
LT
Lithuania
Prior art keywords
psma
targeting compounds
targeting
compounds
Prior art date
Application number
LTEP17169052.2T
Other languages
English (en)
Inventor
Martin G. Pomper
Ronnie C. Mease
Sangeeta Ray
Ying Chen
Original Assignee
The Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Johns Hopkins University filed Critical The Johns Hopkins University
Publication of LT3222617T publication Critical patent/LT3222617T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0412—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K51/0421—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0472—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/14—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 6 and unsubstituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/20—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/342—Prostate diseases, e.g. BPH, prostatitis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEP17169052.2T 2009-03-19 2010-03-19 Psma nukreipti junginiai ir jų naudojimas LT3222617T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16148409P 2009-03-19 2009-03-19
US16148509P 2009-03-19 2009-03-19
US24806709P 2009-10-02 2009-10-02
US24893409P 2009-10-06 2009-10-06

Publications (1)

Publication Number Publication Date
LT3222617T true LT3222617T (lt) 2022-10-25

Family

ID=42740262

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP21198449.7T LT3964502T (lt) 2009-03-19 2010-03-19 Junginiai nukreipti į psma ir jų panaudojimas
LTEP17169052.2T LT3222617T (lt) 2009-03-19 2010-03-19 Psma nukreipti junginiai ir jų naudojimas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP21198449.7T LT3964502T (lt) 2009-03-19 2010-03-19 Junginiai nukreipti į psma ir jų panaudojimas

Country Status (13)

Country Link
US (4) US9056841B2 (lt)
EP (5) EP3964502B1 (lt)
CA (3) CA2755965C (lt)
DK (2) DK3964502T3 (lt)
ES (2) ES2636618T3 (lt)
FI (1) FI3964502T3 (lt)
HR (2) HRP20240952T1 (lt)
HU (1) HUE059796T2 (lt)
LT (2) LT3964502T (lt)
PL (1) PL3222617T3 (lt)
PT (2) PT3222617T (lt)
SI (1) SI3964502T1 (lt)
WO (1) WO2010108125A2 (lt)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2669127C (en) 2006-11-08 2016-09-13 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
US9193763B2 (en) 2007-08-17 2015-11-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US9422234B2 (en) * 2007-11-30 2016-08-23 The Johns Hopkins University Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer
US20180009767A9 (en) 2009-03-19 2018-01-11 The Johns Hopkins University Psma targeted fluorescent agents for image guided surgery
PT3222617T (pt) 2009-03-19 2022-09-30 Univ Johns Hopkins Compostos que têm psma como alvo e as suas utilizações
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
WO2012135592A2 (en) 2011-03-31 2012-10-04 The Johns Hopkins University Theranostic imaging agents and methods of use
WO2013022797A1 (en) 2011-08-05 2013-02-14 Molecular Insight Pharmaceuticals Radiolabeled prostate specific membrane antigen inhibitors
CA2846629C (en) 2011-08-25 2023-08-01 University Of Central Florida Research Foundation, Inc. Methods and compositions comprising a c-terminal bax peptide
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
CN104203942B (zh) * 2011-11-30 2017-04-12 约翰霍普金斯大学 前列腺特异性膜抗原(psma)的同源多价抑制剂和异源多价抑制剂以及其用途
CA2865774A1 (en) * 2012-02-28 2013-09-06 Cornell University Psma as a biomarker for androgen activity in prostate cancer
US9636413B2 (en) 2012-11-15 2017-05-02 Endocyte, Inc. Conjugates for treating diseases caused by PSMA expressing cells
FR2998298B1 (fr) * 2012-11-21 2020-11-20 Univ Bourgogne Synthese de sels d’imidazo[1,2-a]pyrazin-4-ium pour la synthese du 1,4,7-triazacyclononane (tacn) et de ses derives n- et/ou c-fonctionnalises
WO2014110372A1 (en) * 2013-01-14 2014-07-17 Molecular Insight Pharmaceuticals Triazine based radiopharmaceuticals and radioimaging agents
US10117943B2 (en) 2013-05-03 2018-11-06 Yale University Synthetic antibody mimetic compounds (SYAMS) targeting cancer, especially prostate cancer
WO2015057692A1 (en) * 2013-10-14 2015-04-23 The Johns Hopkins University Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy
US10406246B2 (en) 2013-10-17 2019-09-10 Deutsches Kresbsforschungszentrum Double-labeled probe for molecular imaging and use thereof
MX2016005013A (es) * 2013-10-18 2017-02-28 Deutsches Krebsforsch Inhibidores marcados de antigeno prostatico especifico de membrana (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata.
KR102457827B1 (ko) * 2013-11-14 2022-10-24 엔도사이트, 인코포레이티드 양전자 방출 단층 촬영용 화합물
US20170072072A1 (en) * 2014-03-18 2017-03-16 The Methodist Hospital System Ph sensitive fluorescent compounds and methods for tumor detection
CA3215134A1 (en) * 2014-05-06 2015-11-12 The Johns Hopkins University Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy
AU2015258801B2 (en) * 2014-05-16 2020-10-08 Memorial Sloan Kettering Cancer Center One-step labeling of antibodies to high specific activity with actinium-225
CN112999347A (zh) 2014-06-02 2021-06-22 乐天医药生技股份有限公司 酞菁探针及其用途
AU2015290058B2 (en) 2014-07-18 2021-04-01 University Of Central Florida Research Foundation, Inc. Methods and compositions comprising a ct20 peptide
ES2912753T3 (es) 2014-08-24 2022-05-27 Max Planck Gesellschaft Zur Foerderung Der Wss Método para la producción de ésteres activos marcados con 18F y su aplicación ejemplificada por la preparación de un marcador de PET específico de PSMA
WO2016065145A2 (en) * 2014-10-22 2016-04-28 The Johns Hopkins University Psma targeted reversed carbamates and methods of use thereof
US9886665B2 (en) * 2014-12-08 2018-02-06 International Business Machines Corporation Event detection using roles and relationships of entities
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US10973925B2 (en) 2015-04-28 2021-04-13 University Of Central Florida Research Foundation Inc. Methods and compositions for theranostic nanoparticles
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
US20180158559A1 (en) * 2015-06-05 2018-06-07 Ncm Usa Bronx Llc Method and system for producing gallium-68 radioisotope by solid targeting in a cyclotron
MX369556B (es) * 2015-08-06 2019-11-12 Hoffmann La Roche Procesos para la preparacion de derivados acidos de n-acetilgalactosamina (galnac).
US20180236109A1 (en) * 2015-08-20 2018-08-23 Universitat Zu Koln Pain Tracking by PET-imaging (Pain-TraP)
US10842887B2 (en) 2015-09-09 2020-11-24 On Target Laboratories, LLC PSMA-targeted NIR dyes and their uses
US9808538B2 (en) * 2015-09-09 2017-11-07 On Target Laboratories, LLC PSMA-targeted NIR dyes and their uses
PL3356385T3 (pl) 2015-09-30 2021-06-28 Deutsches Krebsforschungszentrum Tagowane 18F inhibitory antygenu błonowego specyficznego dla gruczołu krokowego (PSMA) i ich zastosowanie jako środków do obrazowania w nowotworze gruczołu krokowego
US10898594B2 (en) 2015-10-27 2021-01-26 The Johns Hopkins University PAMAM dendrimer based CEST imaging agents and uses thereof
US10405753B2 (en) * 2015-11-10 2019-09-10 Intuitive Surgical Operations, Inc. Pharmaceutical compositions of near IR closed chain, sulfo-cyanine dyes
MX2018005733A (es) 2015-11-16 2018-08-09 Hoffmann La Roche Fosforamidita de agrupacion de n-acetilgalactosamina (galnac).
PT3925952T (pt) * 2016-03-22 2023-12-13 Univ Johns Hopkins Agentes alvo de alta afinidade direcionados ao antigénio de membrana específica da próstata para endo radioterapia de cancro da próstata
US20170296679A1 (en) 2016-04-18 2017-10-19 Intuitive Surgical Operations, Inc. Compositions of Near IR Closed Chain, Sulfo-Cyanine Dyes and Prostate Specific Membrane Antigen Ligands
WO2018013927A1 (en) 2016-07-14 2018-01-18 University Of Central Florida Research Foundation, Inc. Bi-dota complex-loaded dendritic polymer nanoparticles
CA3043619A1 (en) * 2016-11-23 2018-05-31 Cancer Targeted Technology Llc Albumin-binding psma inhibitors
CN110035996B (zh) 2016-11-28 2022-08-09 拜耳医药股份公司 用于磁共振成像的新型高弛豫性钆螯合物
AU2018210253B2 (en) 2017-01-20 2023-05-04 Regeneron Pharmaceuticals, Inc. Rotatable surgical table
WO2018204477A1 (en) 2017-05-02 2018-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
WO2018215049A1 (en) 2017-05-23 2018-11-29 F. Hoffmann-La Roche Ag Process for galnac oligonucleotide conjugates
US11478558B2 (en) 2017-05-30 2022-10-25 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
CN110678198B (zh) 2017-06-09 2024-02-02 阿文塞勒欧洲有限公司 针对表达通用嵌合抗原受体的免疫细胞的靶向模块及其在治疗癌症、感染和自身免疫性病症中的用途
WO2018232280A1 (en) * 2017-06-15 2018-12-20 The Johns Hopkins University Psma targeted fluorescent agents for image guided surgery
EP3668518A1 (en) 2017-08-18 2020-06-24 Li-Cor, Inc. Sonodynamic therapy
BR112020008011A2 (pt) 2017-10-23 2020-10-27 The Johns Hopkins University agentes de formação de imagem e radioterapêuticos direcionados à proteína-alfa de ativação de fibroblasto (fap-alfa)
JP2021502399A (ja) 2017-11-13 2021-01-28 ドイチェス クレブスフォルシュンクスツェントルム 分子イメージングのための二重標識プローブ及びその使用
JP7324763B2 (ja) * 2017-11-21 2023-08-10 ドイチェス クレブスフォルシュンクスツェントルム 分子イメージングのための二重標識プローブ及びその使用
EP3749653A4 (en) 2018-02-06 2021-12-15 The Johns Hopkins University PSMA TARGETED RADIOHALOGENATED UREA POLYAMINOCARBOXYLATE FOR RADIOTHERAPY AGAINST CANCER
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
WO2019204432A2 (en) * 2018-04-17 2019-10-24 Cornell University Fluorine-18 labeled compositions and their use in imaging of biological tissue
WO2020028323A1 (en) * 2018-07-30 2020-02-06 The Johns Hopkins Universtiy Competitive prostate-specific membrane antigen (psma) binding agents for the reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy
EP3636635A1 (en) 2018-10-11 2020-04-15 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Imaging agents
KR20210095168A (ko) 2018-11-23 2021-07-30 바이엘 악티엔게젤샤프트 조영 매체의 제형 및 그의 제조 방법
JP7546574B2 (ja) 2019-01-30 2024-09-06 コヒレント バイオファーマ （スーチョウ），リミテッド 二重リガンド薬物コンジュゲート及びその使用
CN113117100B (zh) * 2019-12-31 2024-03-01 广东精观生物医药科技有限公司 一种靶向psma的荧光分子探针及其制备方法和应用
WO2022018264A1 (en) * 2020-07-23 2022-01-27 Technische Universität München Silicon-containing ligand compounds
WO2022101352A1 (en) 2020-11-12 2022-05-19 Abx Advanced Biochemical Compounds Gmbh Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks
WO2022216514A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells
CN117479952A (zh) 2021-04-07 2024-01-30 世纪治疗股份有限公司 用于嵌合抗原受体细胞的组合的人工细胞死亡/报告系统多肽及其用途
JP2024513906A (ja) 2021-04-07 2024-03-27 センチュリー セラピューティクス，インコーポレイテッド 人工多能性幹細胞からアルファ－ベータｔ細胞を生成するための組成物および方法
CA3237590A1 (en) 2021-11-09 2023-05-08 James Basilion Psma targeted conjugate compounds and uses thereof
WO2023240147A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof
US20240189460A1 (en) 2022-09-23 2024-06-13 Nuclidium Ag High purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof
WO2024143314A1 (ja) * 2022-12-27 2024-07-04 国立大学法人千葉大学 放射性標識医薬
WO2024150132A1 (en) 2023-01-10 2024-07-18 Sun Pharma Advanced Research Company Limited Ligand-drug conjugates

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6159657A (en) 1999-08-31 2000-12-12 Eastman Kodak Company Thermal imaging composition and member containing sulfonated ir dye and methods of imaging and printing
WO2002024235A2 (en) 2000-05-12 2002-03-28 University Hospital Prochelators of radiometal labeled molecules
US6663847B1 (en) 2000-10-13 2003-12-16 Mallinckrodt Inc. Dynamic organ function monitoring agents
CA2429574C (en) 2000-11-24 2009-02-10 Breath Limited Sterilisation of pharmaceuticals
SI1472541T1 (sl) 2002-01-10 2010-12-31 Univ Johns Hopkins Prikazovalni agensi in postopek prikazovanja naaladase ali psma
FR2903952B1 (fr) 2006-07-21 2009-06-12 Renault Sas Dispositif et procede de surveillance de la commande du braquage de roue arriere directrice.
WO2008109832A2 (en) 2007-03-08 2008-09-12 Visen Medical, Inc. Viable near-infrared fluorochrome labeled cells and methods of making and using same
EP3466928A1 (en) * 2007-06-26 2019-04-10 The Johns Hopkins University Labeled inhibitors of prostate-specific membrane antigen (psma), biological evaluation, and use as imaging agents
US9193763B2 (en) 2007-08-17 2015-11-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US9422234B2 (en) * 2007-11-30 2016-08-23 The Johns Hopkins University Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer
JP2009169768A (ja) 2008-01-17 2009-07-30 Fuji Xerox Co Ltd 情報処理装置及びプログラム
EP2706057B1 (en) * 2008-12-05 2016-04-20 Molecular Insight Pharmaceuticals, Inc. Bis(imidazolyl)compounds and radionuclide complexes
PT3222617T (pt) 2009-03-19 2022-09-30 Univ Johns Hopkins Compostos que têm psma como alvo e as suas utilizações
US20180009767A9 (en) 2009-03-19 2018-01-11 The Johns Hopkins University Psma targeted fluorescent agents for image guided surgery
CN104203942B (zh) * 2011-11-30 2017-04-12 约翰霍普金斯大学 前列腺特异性膜抗原(psma)的同源多价抑制剂和异源多价抑制剂以及其用途
BR112019020109B1 (pt) 2017-03-28 2023-11-07 Baker Hughes, A Ge Company, Llc Método para implantar e recuperar um sistema de bombeamento submersível na tubulação de produção dentro de um furo de poço

Also Published As

Publication number Publication date
EP3222617A1 (en) 2017-09-27
EP3964498A1 (en) 2022-03-09
EP2408755A4 (en) 2012-09-12
HRP20240952T1 (hr) 2024-10-11
US9056841B2 (en) 2015-06-16
PT3222617T (pt) 2022-09-30
US11661402B2 (en) 2023-05-30
CA3131469A1 (en) 2010-09-23
DK3222617T3 (da) 2022-10-03
WO2010108125A2 (en) 2010-09-23
EP3964502B1 (en) 2024-06-12
EP2408755A2 (en) 2012-01-25
EP3964502A1 (en) 2022-03-09
EP2408755B1 (en) 2017-05-03
CA2755965C (en) 2019-04-16
US20150104387A1 (en) 2015-04-16
ES2928480T3 (es) 2022-11-18
SI3964502T1 (sl) 2024-09-30
EP4420730A2 (en) 2024-08-28
US9776977B2 (en) 2017-10-03
PT3964502T (pt) 2024-07-22
EP3964498B1 (en) 2024-06-19
PL3222617T3 (pl) 2023-01-02
US20220259161A1 (en) 2022-08-18
ES2636618T3 (es) 2017-10-06
HRP20221195T1 (hr) 2022-12-09
WO2010108125A3 (en) 2011-03-24
HUE059796T2 (hu) 2022-12-28
CA2755965A1 (en) 2010-09-23
US20120009121A1 (en) 2012-01-12
DK3964502T3 (da) 2024-07-22
US20230348405A1 (en) 2023-11-02
LT3964502T (lt) 2024-08-26
CA3035532A1 (en) 2010-09-23
CA3035532C (en) 2021-10-26
EP3222617B1 (en) 2022-07-06
FI3964502T3 (fi) 2024-07-29

Similar Documents

Publication Publication Date Title
HRP20180718T1 (hr) Oligopeptidni spojevi i njihova upotreba
SI3964502T1 (sl) Spojine, ki ciljajo na PSMA, in njihove uporabe
ZA201303499B (en) Specific diarylhydantoin and diarylthiohydantion compounds
GB0914644D0 (en) Novel agents and uses thereof
HRP20160922T1 (hr) Oligopeptidni spojevi i njihove uporabe
IL214720A0 (en) Pyridocarbazole type compounds and applications thereof
GB0902173D0 (en) Compounds and their use
GB0909768D0 (en) Novel compounds and uses thereof
GB0922510D0 (en) Compound and use
EP2470022A4 (en) COMPOUNDS AND METHODS
GB0903348D0 (en) Compounds and methods relating thereto
GB0905525D0 (en) Compounds and uses
GB0909792D0 (en) Composition and uses thereof
GB0917304D0 (en) Use
GB0908087D0 (en) Novel compounds and uses thereof
PL387177A1 (pl) Związki enaminokarbonylowe i ich zastosowanie
GB0905231D0 (en) Compounds and their use
GB0902013D0 (en) Novel compounds and their use
GB201014319D0 (en) Compounds and uses thereof
GB0910620D0 (en) Agents and uses thereof
GB0907963D0 (en) Use
GB0907472D0 (en) Use
GB0912237D0 (en) Use